hero image

Biogen Statement about Director Lynn Schenk

June 2, 2020 Company Statements

SchenkWe are thankful for the service of Lynn Schenk as a director of IDEC since 1995 and then a director of the merged Biogen company since 2004. Lynn will retire from the Biogen Board at the end of her current term, which expires at the 2020 annual meeting of stockholders.

As a director for more than two decades, Lynn has been part of the remarkable evolution of Biogen from one of the world’s first biotechnology companies to a neuroscience pioneer that today discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Throughout her tenure, Lynn, who was a National Association of Corporate Directors Top 100 Directors honoree in 2017, has been a vital contributor to the company and its Board. She chaired the board’s Nomination & Governance and Risk committees and served on the board’s compensation committee. Lynn’s experience in the public and private sector, as well as her strong public policy, government and legal experience, have been especially important to the company’s success in the highly regulated life sciences industry. She was and continues to be a mentor and champion of women in the company and in science.

Our Board of Directors is deeply grateful for her many contributions and long term of service to Biogen, and wishes her all the best in the future.

thumb
April 28, 2021
Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its supplemental Biologic License Application (sBLA) for a new subcutaneous (SC) route of

Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
April 28, 2021
Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics

Accelerated action on climate, health and equity, including new plastic-free packaging goals for finished goods by 2025 1 Disclosed 2020 global pay equity analysis results 2 and launched enhanced four-part diversity, equity and inclusion strategy Tied a portion of employees’ and executive officers’